<?xml version="1.0" encoding="UTF-8"?><meta xmlns:fo="http://www.w3.org/1999/XSL/Format" xmlns="http://www.w3.org/1999/xhtml" xmlns:xi="http://www.w3.org/2001/XInclude" http-equiv="Content-Type" content="text/html; charset=utf-8" />
<style xmlns:fo="http://www.w3.org/1999/XSL/Format" xmlns:xi="http://www.w3.org/2001/XInclude" type="text/css">
   @media screen{
   .test-story-main legend{
   text-align:center;
   font-size:110%;
   font-weight:bold;
   }
   .test-story-main .nav-tabs{
   font-weight:bold;
   }
   .test-story-main .tds_obxGrpSpl{
   background:#B8B8B8;
   }
   .test-story-main maskByMediaType{
   display:table;
   }
   .test-story-main table tbody tr th{
   font-size:95%
   }
   .test-story-main table tbody tr td{
   font-size: 110%;
   }
   .test-story-main table tbody tr th{
   text-align:left;
   background:#C6DEFF;
   font-size:100%;
   }
   .test-story-main fieldset{
   text-align:center;
   }
   .test-story-main table{
   width:98%;
   border:1px groove;
   table-layout:fixed;
   margin:0 auto;
   border-collapse:collapse;
   }
   .test-story-main table tr{
   border:2px groove;
   
   }
   .test-story-main table th{
   border:2px groove;
   
   }
   .test-story-main table td{
   border:1px groove;
   
   }
   .test-story-main table thead{
   border:1px groove;
   background:#446BEC;
   text-align:center;
   }
   .test-story-main .separator{
   background:rgb(240, 240, 255);
   text-align:left;
   }
   .test-story-main table tbody tr td{
   text-align:left
   }
   .test-story-main .noData{
   background:#B8B8B8;
   }
   .test-story-main .childField{
   background:#B8B8B8;
   }
   .test-story-main .title{
   text-align:left;
   }
   .test-story-main h3{
   text-align:center;
   page-break-inside:avoid;
   }
   .test-story-main h2{
   text-align:center;
   }
   .test-story-main h1{
   text-align:center;
   }
   .test-story-main .pgBrk{
   padding-top:15px;
   }
   .test-story-main .er7Msg{
   width:100%;
   }
   .test-story-main .embSpace{
   padding-left:15px;
   }
   .test-story-main .accordion-heading{
   font-weight:bold;
   font-size:90%;
   }
   .test-story-main .accordion-heading i.fa:after{
   content:"\00a0 ";
   }
   .test-story-main panel{
   margin:10px 5px 5px 5px;
   }
   }
   
   @media print{
   .test-story-main legend{
   text-align:center;
   font-size:110%;
   font-weight:bold;
   }
   .test-story-main .nav-tabs{
   font-weight:bold;
   }
   .test-story-main .obxGrpSpl{
   background:#B8B8B8;
   }
   .test-story-main maskByMediaType{
   display:table;
   }
   .test-story-main table tbody tr th{
   font-size:90%
   }
   .test-story-main table tbody tr td{
   font-size:90%;
   }
   .test-story-main table tbody tr th{
   text-align:left;
   background:#C6DEFF;
   
   }
   .test-story-main table thead tr th{
   text-align:center;
   background:#4682B4;
   
   }
   .test-story-main fieldset{
   text-align:center;
   page-break-inside:avoid;
   }
   .test-story-main table{
   width:98%;
   border:1px groove;
   table-layout:fixed;
   margin:0 auto;
   page-break-inside:avoid;
   border-collapse:collapse;
   }
   .test-story-main table tr{
   border:2px groove;
   }
   .test-story-main table th{
   border:2px groove;
   }
   .test-story-main table td{
   border:1px groove;
   }
   .test-story-main table thead{
   border:1px groove;
   background:#446BEC;
   text-align:left;
   }
   .test-story-main .separator{
   background:rgb(240, 240, 255);
   text-align:left;
   }
   .test-story-main table tbody tr td{
   text-align:left;
   }
   .test-story-main .noData{
   background:#B8B8B8;
   }
   .test-story-main .childField{
   background:#B8B8B8;
   }
   .test-story-main .tds_title{
   text-align:left;
   margin-bottom:1%
   }
   .test-story-main h3{
   text-align:center;
   }
   .test-story-main h2{
   text-align:center;
   }
   .test-story-main h1{
   text-align:center;
   }
   .test-story-main .tds_pgBrk{
   page-break-after:always;
   }
   .test-story-main #er7Message table{
   border:0px;
   width:80%
   }
   .test-story-main #er7Message td{
   background:#B8B8B8;
   font-size:65%;
   margin-top:6.0pt;
   border:0px;
   text-wrap:preserve-breaks;
   white-space:pre;
   }
   .test-story-main .er7Msg{
   width:100%;
   font-size:80%;
   }
   .test-story-main .er7MsgNote{
   width:100%;
   font-style:italic;
   font-size:80%;
   }
   .test-story-main .embSpace{
   padding-left:15px;
   }
   .test-story-main .embSubSpace{
   padding-left:25px;
   }
   .test-story-main .accordion-heading{
   font-weight:bold;
   font-size:90%;
   }
   .test-story-main .accordion-heading i.fa:after{
   content:"\00a0 ";
   }
   .test-story-main panel{
   margin:10px 5px 5px 5px;
   }
   }
</style>
<!-- generated by TestStory_v1.xslt Version:1.0   Profile:TestStory-->
<fieldset>
	<div class="test-story-main">
		<tabset>
			<tab heading="FULL"  vertical="false">
				<div class="panel-body">
					<div class="panel-body"><table><tr><th>Description</th></tr><tr><td><p>The provider reviews the full list of vaccine inventory.</p></td></tr></table></div><br/><div class="panel-body"><table><tr><th>Comments</th></tr><tr><td><p>No Comments</p></td></tr></table></div><br/><div class="panel-body"><table><tr><th>Pre-condition</th></tr><tr><td><p>Inventory has been entered into the EMR.</p></td></tr></table></div><br/><div class="panel-body"><table><tr><th>Post-Condition</th></tr><tr><td><p>The list of available inventory is displayed.</p></td></tr></table></div><br/><div class="panel-body"><table><tr><th>Test Objectives</th></tr><tr><td><p><span style="font-weight: bold; font-style: italic;">Display Available Vaccine Antigens:&nbsp;</span><span style="font-style: normal; font-weight: normal;">The system presents a list of vaccine antigens available for administration to patients (i.e., private stock Vs. specific guarantee program).</span></p></td></tr></table></div><br/><div class="panel-body"><table><tr><th>Evaluation Criteria</th></tr><tr><td><p>The EMR inventory shows (minimally):</p><div><br></div><div><p>1. Manufacturer: Novartis Vaccines and Diagnostics Ltd<br>NDC:66521-0113-02<br>Product Name:FLUVIRIN<br>Lot#:8L4B3521<br>Expiration Date:12/31/2019<br>Vaccine source:VFC<br>Quantity:25 Syringes (or doses)</p><p>2. Manufacturer: Sanofi Pasteur Inc.<br>NDC:49281-0413-58<br>Product Name:FLUZONE QUADRIVALENT<br>Lot#:D8043IN8422<br>Expiration Date:12/31/2019<br>Vaccine source:VFC<br>Quantity:15 Vials (or doses)</p><p>3. Manufacturer: Sanofi Pasteur Inc.<br>NDC:49281-0413-58<br>Product Name:FLUZONE QUADRIVALENT<br>Lot#:D8043IN8855</p><p>Expiration Date:12/31/2019<br>Vaccine source:Non-VFC<br>Quantity:12 Vials (or doses)</p><p>4. Manufacturer: GlaxoSmithKline Biologicals SA<br>NDC:58160-0820-43<br>Product Name:hepatitis B vaccine, pediatric or pediatric/adolescent dosage (CVX 08) ENGERIX-B (NDC 58160-0820-43)<br>Lot#:6332FK18<br>Expiration Date:6/15/2018<br>Vaccine source:Non-VFC<br>Quantity:18 Syringes (or doses)</p><p>5. Manufacturer: GlaxoSmithKline Biologicals SA<br>NDC:58160-0820-43<br>Product Name:hepatitis B vaccine, pediatric or pediatric/adolescent dosage (CVX 08) ENGERIX-B (NDC 58160-0820-43)<br>Lot#:6332FK26<br>Expiration Date:12/31/2019<br>Vaccine source:Non-VFC<br>Quantity:20 Syringes (or doses)</p><p><br></p><p>6. Manufacturer: GlaxoSmithKline Biologicals SA<br>NDC:58160-0811-43<br>Product Name:DTaP-hepatitis B and poliovirus vaccine (CVX 110) Pediarix (NDC 58160-0811-43)<br>Lot#:6559FK32<br>Expiration Date:12/31/2019<br>Vaccine source:Non-VFC<br>Quantity:16 Syringes (or doses)</p><div style="font-size: 13.3333px;"><div style="font-size: 10pt;"><br></div></div><div><br></div><div><br></div></div></td></tr></table></div><br/><div class="panel-body"><table><tr><th>Notes</th></tr><tr><td><p><span style="font-family: Arial, Verdana; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: normal;">This test step is introduced in 2018 and will be considered an evaluation year for the test step. Tester should document feedback and issues. Tester should also document</span><span style="font-size: 13.3333px;">&nbsp;how quantity is displayed and what is present (e.g. volume, # doses)</span></p></td></tr></table></div><br/>
				</div>
			</tab>
			<tab heading="Description" vertical="false"><div class="panel-body"><table><tr><th>Description</th></tr><tr><td><p>The provider reviews the full list of vaccine inventory.</p></td></tr></table></div></tab><tab heading="Comments" vertical="false"><div class="panel-body"><table><tr><th>Comments</th></tr><tr><td><p>No Comments</p></td></tr></table></div></tab><tab heading="Pre-condition" vertical="false"><div class="panel-body"><table><tr><th>Pre-condition</th></tr><tr><td><p>Inventory has been entered into the EMR.</p></td></tr></table></div></tab><tab heading="Post-Condition" vertical="false"><div class="panel-body"><table><tr><th>Post-Condition</th></tr><tr><td><p>The list of available inventory is displayed.</p></td></tr></table></div></tab><tab heading="Test Objectives" vertical="false"><div class="panel-body"><table><tr><th>Test Objectives</th></tr><tr><td><p><span style="font-weight: bold; font-style: italic;">Display Available Vaccine Antigens:&nbsp;</span><span style="font-style: normal; font-weight: normal;">The system presents a list of vaccine antigens available for administration to patients (i.e., private stock Vs. specific guarantee program).</span></p></td></tr></table></div></tab><tab heading="Evaluation Criteria" vertical="false"><div class="panel-body"><table><tr><th>Evaluation Criteria</th></tr><tr><td><p>The EMR inventory shows (minimally):</p><div><br></div><div><p>1. Manufacturer: Novartis Vaccines and Diagnostics Ltd<br>NDC:66521-0113-02<br>Product Name:FLUVIRIN<br>Lot#:8L4B3521<br>Expiration Date:12/31/2019<br>Vaccine source:VFC<br>Quantity:25 Syringes (or doses)</p><p>2. Manufacturer: Sanofi Pasteur Inc.<br>NDC:49281-0413-58<br>Product Name:FLUZONE QUADRIVALENT<br>Lot#:D8043IN8422<br>Expiration Date:12/31/2019<br>Vaccine source:VFC<br>Quantity:15 Vials (or doses)</p><p>3. Manufacturer: Sanofi Pasteur Inc.<br>NDC:49281-0413-58<br>Product Name:FLUZONE QUADRIVALENT<br>Lot#:D8043IN8855</p><p>Expiration Date:12/31/2019<br>Vaccine source:Non-VFC<br>Quantity:12 Vials (or doses)</p><p>4. Manufacturer: GlaxoSmithKline Biologicals SA<br>NDC:58160-0820-43<br>Product Name:hepatitis B vaccine, pediatric or pediatric/adolescent dosage (CVX 08) ENGERIX-B (NDC 58160-0820-43)<br>Lot#:6332FK18<br>Expiration Date:6/15/2018<br>Vaccine source:Non-VFC<br>Quantity:18 Syringes (or doses)</p><p>5. Manufacturer: GlaxoSmithKline Biologicals SA<br>NDC:58160-0820-43<br>Product Name:hepatitis B vaccine, pediatric or pediatric/adolescent dosage (CVX 08) ENGERIX-B (NDC 58160-0820-43)<br>Lot#:6332FK26<br>Expiration Date:12/31/2019<br>Vaccine source:Non-VFC<br>Quantity:20 Syringes (or doses)</p><p><br></p><p>6. Manufacturer: GlaxoSmithKline Biologicals SA<br>NDC:58160-0811-43<br>Product Name:DTaP-hepatitis B and poliovirus vaccine (CVX 110) Pediarix (NDC 58160-0811-43)<br>Lot#:6559FK32<br>Expiration Date:12/31/2019<br>Vaccine source:Non-VFC<br>Quantity:16 Syringes (or doses)</p><div style="font-size: 13.3333px;"><div style="font-size: 10pt;"><br></div></div><div><br></div><div><br></div></div></td></tr></table></div></tab><tab heading="Notes" vertical="false"><div class="panel-body"><table><tr><th>Notes</th></tr><tr><td><p><span style="font-family: Arial, Verdana; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: normal;">This test step is introduced in 2018 and will be considered an evaluation year for the test step. Tester should document feedback and issues. Tester should also document</span><span style="font-size: 13.3333px;">&nbsp;how quantity is displayed and what is present (e.g. volume, # doses)</span></p></td></tr></table></div></tab>
		</tabset>
	</div>
</fieldset>